COVID-19 HSE Weekly Booster Vaccination Figures

Description

Please see FAQ for latest information on COVID-19 Data Hub Data Flows   https://covid-19.geohive.ie/pages/helpfaqs

Category Field Label Field Display Name Explanation
ExtractDate ExtractDate Date the data is extracted
Latitude Latitude
Longitude Longitude
EpiWeek EpiWeek Details of epidemiological weeks available here https://www.hpsc.ie/notifiablediseases/resources/epidemiologicalweeks/
Week Week Details of epidemiological weeks available here https://www.hpsc.ie/notifiablediseases/resources/epidemiologicalweeks/
WeeklyBoosterVaccines Weekly Booster Vaccines Amount of boosters given during week
Vaccine Brand AstraZeneca AstraZeneca
Janssen Janssen
Moderna Moderna
Pfizer Pfizer
Additional Doses by Brand AD_AstraZeneca AdditionalDoses AstraZeneca
AD_Janssen AdditionalDoses Janssen
AD_Moderna AdditionalDoses Moderna
AD_Pfizer AdditionalDoses Pfizer
Immunocompromised Doses by Brand ID_AstraZeneca ImmunocompromisedDoses AstraZeneca
ID_Janssen ImmunocompromisedDoses Janssen
ID_Moderna ImmunocompromisedDoses Moderna
ID_Pfizer ImmunocompromisedDoses Pfizer
Gender Male Male
Female Female
Not Assigned NA
Age Group Additional Dose AD_Age0to9 AdditionalDose Age5to11 Additional Dose Age 5 to 11
AD_Age10to19 AdditionalDose Age12to19 Additional Dose Age 12 to 19
AD_Age20to29 AdditionalDose Age20to29 Additional Dose Age 20 to 29
AD_Age30to39 AdditionalDose Age30to39 Additional Dose Age 30 to 39
AD_Age40to49 AdditionalDose Age40to49 Additional Dose Age 40 to 49
AD_Age50to59 AdditionalDose Age50to59 Additional Dose Age 50 to 59
AD_Age60to69 AdditionalDose Age60to69 Additional Dose Age 60 to 69
AD_Age70to79 AdditionalDose Age70to79 Additional Dose Age 70 to 79
AD_Age80_ AdditionalDose Age80+ Additional Dose Age 80+
AD_NA AdditionalDose NotAssigned Additional Dose Not Assigned To Age Group
Age Group Additional Dose Cumulative AD_Age0to9_Cum AdditionalDose Cumulative Age5to11 Additional Dose Cumulative Age 5 to 11
AD_Age10to19_Cum AdditionalDose Cumulative Age12to19 Additional Dose Cumulative Age 12 to 19
AD_Age20to29_Cum AdditionalDose Cumulative Age20to29 Additional Dose Cumulative Age 20 to 29
AD_Age30to39_Cum AdditionalDose Cumulative Age30to39 Additional Dose Cumulative Age 30 to 39
AD_Age40to49_Cum AdditionalDose Cumulative Age40to49 Additional Dose Cumulative Age 40 to 49
AD_Age50to59_Cum AdditionalDose Cumulative Age50to59 Additional Dose Cumulative Age 50 to 59
AD_Age60to69_Cum AdditionalDose Cumulative Age60to69 Additional Dose Age 60 to 69
AD_Age70to79_Cum AdditionalDose Cumulative Age70to79 Additional Dose Age 70 to 79
AD_Age80__Cum AdditionalDose Cumulative Age80+ Additional Dose Cumulative Age 80+
AD_NA_Cum AdditionalDose Cumulative Not Assigned Additional Dose Cumulative Not Assigned To Age Group
Age Group Immunocompromised Dose ID_Age0to9 ImmunocompromisedDoses Age5to11 Immunocompromised Dose Age 5 to 11
ID_Age10to19 ImmunocompromisedDoses Age12to19 Immunocompromised Dose Age 12 to 19
ID_Age20to29 ImmunocompromisedDoses Age20to29 Immunocompromised Dose Age 20 to 29
ID_Age30to39 ImmunocompromisedDoses Age30to39 Immunocompromised Dose Age 30 to 39
ID_Age40to49 ImmunocompromisedDoses Age40to49 Immunocompromised Dose Age 40 to 49
ID_Age50to59 ImmunocompromisedDoses Age50to59 Immunocompromised Dose Age 50 to 59
ID_Age60to69 ImmunocompromisedDoses Age60to69 Immunocompromised Dose Age 60 to 69
ID_Age70to79 ImmunocompromisedDoses Age70to79 Immunocompromised Dose Age 70 to 79
ID_Age80_ ImmunocompromisedDoses Age80+ Immunocompromised Dose Age 80+
ID_NA ImmunocompromisedDoses Not Assigned Immunocompromised Dose Not Assigned To Age Group
Age Group Immunocompromised Dose Cumulative ID_Age0to9_Cum ImmunocompromisedDoses Cumulative Age5to11 Immunocompromised Dose Cumulative Age 5 to 11
ID_Age10to19_Cum ImmunocompromisedDoses Cumulative Age12to19 Immunocompromised Dose Cumulative Age 12 to 19
ID_Age20to29_Cum ImmunocompromisedDoses Cumulative Age20to29 Immunocompromised Dose Cumulative Age 20 to 29
ID_Age30to39_Cum ImmunocompromisedDoses Cumulative Age30to39 Immunocompromised Dose Cumulative Age 30 to 39
ID_Age40to49_Cum ImmunocompromisedDoses Cumulative Age40to49 Immunocompromised Dose Cumulative Age 40 to 49
ID_Age50to59_Cum ImmunocompromisedDoses Cumulative Age50to59 Immunocompromised Dose Cumulative Age 50 to 59
ID_Age60to69_Cum ImmunocompromisedDoses Cumulative Age60to69 Immunocompromised Dose Age 60 to 69
ID_Age70to79_Cum ImmunocompromisedDoses Cumulative Age70to79 Immunocompromised Dose Age 70 to 79
ID_Age80__Cum ImmunocompromisedDoses Cumulative Age80+ Immunocompromised Dose Cumulative Age 80+
ID_NA_Cum ImmunocompromisedDoses Cumulative NotAssigned Immunocompromised Dose Cumulative Not Assigned To Age Group
Immunocompromised Dose and Additional Dose Administered As A Percentage of Population In Each Age Group BoosterPer_Age0to9 IDandADTotal % of Population Age5to11 Immunocompromised Dose and Additional Dose Administered As A Percentage of Population In Age Group 5 to 11
BoosterPer_Age10to19 IDandADTotal % of Population Age12to19 Immunocompromised Dose and Additional Dose Administered As A Percentage of Population In Age Group 12 to 19
BoosterPer_Age20to29 IDandADTotal % of Population Age20to30 Immunocompromised Dose and Additional Dose Administered As A Percentage of Population In Age Group 20 to 29
BoosterPer_Age30to39 IDandADTotal % of Population Age30to40 Immunocompromised Dose and Additional Dose Administered As A Percentage of Population In Age Group 30 to 39
BoosterPer_Age40to49 IDandADTotal % of Population Age40to50 Immunocompromised Dose and Additional Dose Administered As A Percentage of Population In Age Group 40 to 49
BoosterPer_Age50to59 IDandADTotal % of Population Age50to60 Immunocompromised Dose and Additional Dose Administered As A Percentage of Population In Age Group 50 to 59
BoosterPer_Age60to69 IDandADTotal % of Population Age60to70 Immunocompromised Dose and Additional Dose Administered As A Percentage of Population In Age Group 60 to 69
BoosterPer_Age70to79 IDandADTotal % of Population Age70to80 Immunocompromised Dose and Additional Dose Administered As A Percentage of Population In Age Group 70 to 79
BoosterPer_Age80_ IDandADTotal % of Population Age80+ Immunocompromised Dose and Additional Dose Administered As A Percentage of Population In Age Group 80+
BoosterPer_NA IDandADTotal % of Population Not Assigned Immunocompromised Dose and Additional Dose Administered As A Percentage of Population Not Assigned To Age Group

Resources

Name Format Description Link
15 https://opendata-geohive.hub.arcgis.com/datasets/2a4814b66d0d459cbb80dea30f61fbfe_0.geojson?outSR=%7B%22latestWkid%22%3A3857%2C%22wkid%22%3A102100%7D
57 https://opendata-geohive.hub.arcgis.com/datasets/2a4814b66d0d459cbb80dea30f61fbfe_0.zip?outSR=%7B%22latestWkid%22%3A3857%2C%22wkid%22%3A102100%7D
8 https://opendata-geohive.hub.arcgis.com/datasets/2a4814b66d0d459cbb80dea30f61fbfe_0.csv?outSR=%7B%22latestWkid%22%3A3857%2C%22wkid%22%3A102100%7D
3 https://services-eu1.arcgis.com/z6bHNio59iTqqSUY/arcgis/rest/services/COVID19_HSE_vaccine_booster_dose_weekly/FeatureServer/0
25 https://opendata-geohive.hub.arcgis.com/datasets/2a4814b66d0d459cbb80dea30f61fbfe_0.kml?outSR=%7B%22latestWkid%22%3A3857%2C%22wkid%22%3A102100%7D
21 https://opendata-geohive.hub.arcgis.com/maps/2a4814b66d0d459cbb80dea30f61fbfe_0

Tags

  • hse
  • noca
  • vaccinations
  • hpsc
  • ordnance-survey-ireland
  • dgihealth
  • osi
  • geohive
  • covid
  • ireland
  • health
  • covid-19
  • department-of-health

Topics

  • HEAL

Categories